If your current eczema (Atopic Dermatitis, or AD) treatment isn't adequately relieving the itchy skin and rash, RINVOQ® may help.
Ask your doctor if RINVOQ® could be right for you.
RINVOQ® may help to reduce rashes, itching and flares, in adults and adolescents 12 years or older who are living with moderate to severe Atopic Dermatitis.
For some people with Atopic Dermatitis, management strategies involving combinations of the below may not be enough to relieve symptoms such as itchy skin and rash:
- Topical emollient and antiseptic creams and lotions
- Topical or systemic corticosteroid treatments
- General measures such as avoidance of skin irritants, triggering foods and allergens.
Everyday activities can be affected by both the physical and psychological effects of your symptoms. RINVOQ® may help to reduce your discomfort and allow you to enjoy daily life once more.
‡
RINVOQ® for Atopic Dermatitis in New Zealand
RINVOQ® is only available with a prescription, so if you are still experiencing symptoms of Atopic Dermatitis despite your current treatment, consult your dermatologist to see if RINVOQ® is right for you.
RINVOQ® is not currently subsidised for Atopic Dermatitis and you will need to pay the full cost of this medication.
‡The 30mg tablet may not always be available in pharmacy.
Tackle your eczema with RINVOQ®
The efficacy and safety of RINVOQ® was assessed in 2 randomised, double-blind clinical trials involving over 1,680 adult and adolescent patients with moderate to severe eczema (atopic dermatitis)1,2
Collectively, these trials concluded that compared to the placebo groups, a greater percentage of patients who received RINVOQ® achieved significant improvement in their AD symptoms—including skin clearance* and itch** — at week 16.†
Ongoing benefit was seen out to week 52 in the clinical trial extension studies.1-3
* Primary measures evaluated to assess skin clearance were vIGA-AD and EASI-75. EASI-90 was a secondary endpoint.
vIGA-AD (validated Investigator Global Assessment of Atopic Dermatitis) is a point score system that assesses severity of AD symptoms: erythema (redness), induration/papulation (swelling) and oozing/crusting, on an increasing severity scale of 0 to 4. A vIGA-AD score of 0 or 1 means AD is clear or almost clear.
The EASI (Eczema Area & Severity Index) score is a tool used to measure the extent and severity of AD. AD symptoms (erythema (redness), edema/papulation (swelling, scratches and lichenification (leathery thickening of the skin with exaggerated skin lines)) are assessed across four different body parts to produce an EASI score. EASI-75 (or EASI-90) indicates an improvement of at least 75% (or 90%) from baseline and is considered clinically meaningful.
** Measured by a ≥4-point reduction in the Worst Pruritis NRS. The NRS (numerical rating scale) is a simple, highly reliable and popular measure of itch severity using a sliding scale of 0 (‘no itch’) to 10 (‘worst imaginable itch’). Patients rate the intensity of their worst pruritis (itch) using the scale. A ≥4-point reduction is considered clinically meaningful.
†p
<0.001 vs placebo group
Frequently Asked Questions about RINVOQ®
When should I expect to see and feel an improvement?
Clinical trials (see results in yellow box above) suggest you may see significant improvement in skin clearance and itch relief by 16 weeks, and possibly rapid improvements within the first week for itch and the second week for skin clearance.1,2 However, some patients will not respond within these timeframes. It’s important to be patient and stay on track with your dosing schedule.1
Will the benefits last?
During the clinical trial extension period, ongoing observations suggest that those patients taking RINVOQ® who experienced improvements in skin clearance and itch relief at 16 weeks will continue to see them up to 52 weeks.2,3
Will RINVOQ® cure my disease?
Unfortunately, currently there are no treatments available that can cure eczema. RINVOQ® will not cure your condition but can help manage your symptoms.
What else can I do to take care of my disease besides taking medications?
There are several ways to better manage AD4-7:
- Understand the disorder and be fully informed by your healthcare provider.
- Keep your skin moisturised and clean with daily baths or showers.
- Where possible avoid triggers that can directly inflame the skin, such as fabrics, chemicals and overly humid or dry environments.
- Try to avoid scratching in response to itch, which can make your rash worse.
- Food allergies do not cause AD, but they may exacerbate it. So can avoidance diets however, so do not cut specific foods from your diet without consulting your doctor.
- Counselling and cognitive behavioural therapy can be beneficial in managing the psychological effects of AD.
What that means for you
RINVOQ® may help to fight the intense itch and rash of moderate to severe AD in a once-daily treatment. But first you’ll need discuss with your dermatologist whether RINVOQ® could be a part of your treatment plan.